Jeil Pharmaceutical Co., Ltd.: Observational study in Erosive Gastroesophageal Reflux Disease (3000 participants)
Jeil Pharmaceutical Co., Ltd.: Observational study in Erosive Gastroesophageal Reflux Disease (3000 participants). Its enrollment of 3,000 is top-decile (98th percentile of 8,879 records). Dated 9 days ago, it is in the active follow-up window. Score 75/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 3,000 · 98th percentile of 8,879 ClinicalTrialStartPulse records · 37.5x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Jeil Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Zastaprazan Citrate |
| NCT ID | NCT07894939 |
| Phase | Observational |
| Status | recruiting |
| Conditions | Erosive Gastroesophageal Reflux Disease |
| Intervention types | drug |
| Target enrollment | 3000 |
| Site countries | South Korea |
| Posted | 2026-10-26 |
| Planned start | 2024-11-02 |
| Event | Newly registered study |
| Event date | 2026-10-26 |
| enrollment percentile | 98th of 8,879 (median 80, 37.5x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Jeil Pharmaceutical Co., Ltd.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Jeil Pharmaceutical Co. + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-26
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Jeil Pharmaceutical Co., Ltd. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Jeil Pharmaceutical Co., Ltd.'s enrollment: 98th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
75 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- 3000 participants planned.
What is the ClinicalTrialStartPulse record for Jeil Pharmaceutical Co., Ltd.?
Jeil Pharmaceutical Co., Ltd. registered a Observational study (NCT07894939) in Erosive Gastroesophageal Reflux Disease targeting 3000 participants, posted 2026-10-26.
How does Jeil Pharmaceutical Co., Ltd. compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 3,000 is 37.5x the median of 80 across 8,879 records. It is fresh: dated 9 days ago, inside the window where early outreach matters most. Its Score of 75/100 puts it among the stronger signals in this feed.
Jeil Pharmaceutical Co., Ltd. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Jeil Pharmaceutical Co., Ltd. | NONUS | 3,000 | 98th | 2026-10-26 |
| Hoffmann-La Roche | NONUS | 1,800 | 96th | 2026-10-30 |
| Janssen Pharmaceutica N.V., Belgium | NONUS | 1,314 | 95th | 2026-11-03 |
| Janssen-Cilag International NV | NONUS | 135 | 68th | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Observational ClinicalTrialStartPulse: Outside the US only
How to monitor Jeil Pharmaceutical Co., Ltd. and peer observational records
Get new ClinicalTrialStartPulse records like Jeil Pharmaceutical Co., Ltd. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.